Hansa Biopharma AB (HNSA)

Stockholm


	Symbol		Exchange		Currency
	HNSA		Stockholm		SEK	Real-time
	HNSAs		BATS Europe		SEK	Delayed
	24H		Frankfurt		EUR	Delayed

Currency in SEK

30.40

-0.12(-0.39%)

Closed11:30:59

Fair Value

Day's Range

30.26

30.70

52 wk Range

22.00

57.30

HNSA Income Statement

Explore the detailed Hansa Biopharma AB income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Hansa Biopharma AB's growth trends and overall financial health.

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

3.36

6.1

33.88

154.53

134.09

Total Revenues Growth

+0.18%

+81.27%

+455.56%

+356.12%

-13.22%

Cost Of Revenues

0.87

1

15.43

38.48

63.14

Gross Profit

2.5

5.1

18.45

116.05

70.95

Gross Profit Growth

+2.29%

+104.2%

+261.75%

+528.88%

-38.86%

Gross Profit Margin %

74.26%

83.65%

54.47%

75.1%

52.91%

Other Operating Expenses, Total

360.09

430.18

558.03

692.17

859.45

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+47.45%	+19.46%	+29.72%	+24.04%	+24.17%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	192.95	227.19	230.76	346.24	411.33
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	167.31	202.99	327.27	337.86	450.49
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-0.17	-	-	8.06	-2.38

Operating Income

-357.6

-425.08

-539.58

-576.12

-788.5

Operating Income Growth

-47.9%

-18.87%

-26.94%

-6.77%

-36.86%

EBIT Margin %

-10,630.05%

-6,970.76%

-1,592.72%

-372.83%

-588.02%

Net Interest Expenses

-0.35

0.13

-0.63

-34.83

-77.46

Net Interest Expenses Growth

+46.79%

+137.64%

-578.63%

-5,455.5%

-122.37%

Interest Expense, Total

-0.47

-0.26

-0.69

-43.67

-105.52

Interest And Investment Income

0.12

0.39

0.07

8.83

28.06

Other Non Operating Expenses, Total

-1.65

4.05

-7.92

0.97

35.14

EBT, Excl. Unusual Items

-359.59

-420.89

-548.13

-609.98

-830.81

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-

-

-

-

-

EBT, Incl. Unusual Items

-359.59

-420.89

-548.13

-609.98

-830.81

EBT, Incl. Unusual Items Growth

-44.99%

-17.05%

-30.23%

-11.28%

-36.2%

EBT, Incl. Unusual Items Margin

-10,689.42%

-6,902.15%

-1,617.95%

-394.74%

-619.57%

Income Tax Expense

0.42

-0.04

0.15

1.16

0.91

Net Income to Company

-360.01

-420.85

-548.28

-611.13

-831.72

Minority Interest

-

-

-

-

-

Net Income

-360.01

-420.85

-548.28

-611.13

-831.72

Net Income Growth

-45.18%

-16.9%

-30.28%

-11.46%

-36.09%

Net Income Margin %

-10,701.81%

-6,901.49%

-1,618.4%

-395.49%

-620.25%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

-360.01

-420.85

-548.28

-611.13

-831.72

Basic EPS - Continuing Operations

-9

-9.98

-12.33

-13.6

-15.83

Basic EPS - Continuing Operations Growth

-39.03%

-10.92%

-23.55%

-10.35%

-16.37%

Diluted EPS - Continuing Operations

-9

-9.98

-12.33

-13.6

-15.83

Diluted EPS - Continuing Operations Growth

-39.1%

-10.87%

-23.55%

-10.35%

-16.37%

Basic Weighted Average Shares Outstanding

40.02

42.18

44.47

44.92

52.54

Diluted Weighted Average Shares Outstanding

40.02

42.18

44.47

44.92

52.54

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

-355.47

-422.29

-538.06

-573.71

-785.67

EBITDA Growth

-47.79%

-18.8%

-27.41%

-6.63%

-36.95%

EBITDA Margin %